Iovance Biotherapeutics
IOVA
IOVA
218 hedge funds and large institutions have $1.44B invested in Iovance Biotherapeutics in 2023 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 90 increasing their positions, 65 reducing their positions, and 39 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding in top 10
Funds holding in top 10: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
0.67% less ownership
Funds ownership: 91.54% → 90.87% (-0.67%)
4% less funds holding
Funds holding: 227 → 218 (-9)
21% less first-time investments, than exits
New positions opened: 31 | Existing positions closed: 39
Holders
218
Holding in Top 10
3
Calls
$10.9M
Puts
$5.88M
Top Buyers
| 1 | +$48.3M | |
| 2 | +$32M | |
| 3 | +$29.6M | |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$16.8M |
| 5 |
HRCM
Hood River Capital Management
Palm Beach Gardens,
Florida
|
+$13.9M |
Top Sellers
| 1 | -$29.5M | |
| 2 | -$18.9M | |
| 3 | -$15M | |
| 4 |
DM
Deerfield Management
New York
|
-$11.2M |
| 5 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
-$11M |